Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone

Acta Myologica

Volumn 31, Issue MAY, 2012, Pages 31-39

  Lehmann Horn, Frank ^a   Weber, Marc André ^b   Nagel, Armin M ^c   Meinck, Hans Michael ^b   Breitenbach, Simon ^a   Scharrer, Johannes ^a   Jurkat Rott, Karin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cytotoxic oedema; Duchenne muscular dystrophy; Eplerenone

Indexed keywords

ALDOSTERONE ANTAGONIST; AMPHOTERICIN B; CARBONATE DEHYDRATASE INHIBITOR; EPLERENONE; SODIUM ION;

ADULT; ARTICLE; CASE REPORT; DIAPHRAGM; DUCHENNE MUSCULAR DYSTROPHY; EDEMA; FEMALE; HUMAN; HUMAN CELL; MUSCLE CELL; MUSCLE STRENGTH; NONHUMAN; PATHOGENESIS; PILOT STUDY; RAT; REPOLARIZATION;

ADULT; ALDOSTERONE ANTAGONISTS; ANIMALS; DIAPHRAGM; EDEMA; FEMALE; FOREARM; HUMANS; LEG; MAGNETIC RESONANCE IMAGING; MEMBRANE POTENTIALS; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; RATS; RATS, WISTAR; SPIRONOLACTONE; YOUNG ADULT;

EID: 84861659184     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Duchenne GBA. Recherches sur la paralysie pseudo-hypertophique ou paralysie myosclérosique. Archives Générales de Médicine 1868;11:25.
2. Marden FA, Connolly AM, Siegel MJ, et al. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 2005;34:140-8. (Pubitemid 40305454)
3. + overload, major and reversible contributors to weakness by ion channel leaks. Proc Natl Acad Sci USA 2009;106:4036-41.
4. Nagel AM, Amarteifio E, Lehmann-Horn F, et al. 3 Tesla sodium inversion recovery magnetic resonance imaging enables improved visualization of intracellular sodium content changes in muscular channelopathies. Invest Radiol 201;46:759-66.
5. 23Na) MRI detects elevated muscular sodium concentration in Duchenne muscular dystrophy. Neurology 2011;77:2017-24.
6. 23Na overload in patients with hyperkalemic periodic paralysis and permanent weakness. Radiology 2012 [in press].
7. LoVecchio F, Jacobson S. Approach to generalized weakness and peripheral neuromuscular disease. Emerg Med Clin North Am 1997;15:605-23. (Pubitemid 27330715)
8. Friedmann-Bette B, Bauer T, Kinscherf R, et al. Effects of strength training with eccentric overload on muscle adaptation in male athletes. Eur J Appl Physiol 2010;108:821-36.
9. Soltanzadeh P, Friez MJ, Dunn D, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord 2010;20:499-504.
10. Kolla V, Litwack G. Transcriptional regulation of the human Na/K ATPase via the human mineralocorticoid receptor. Mol Cell Biochem 2000;204:35-40. (Pubitemid 30111755)
11. Estrada M, Liberona JL, Miranda M, et al. E. Aldosterone- and testosterone-mediated intracellular calcium response in skeletal muscle cell cultures. Am J Physiol Endocrinol Metab 2000;279:E132-9. (Pubitemid 30609954)
12. Sakakibara H, Engel AG, Lambert EH. Duchenne dystrophy: ultrastructural localization of the acetylcholine receptor and intracellular microelectrode studies of neuromuscular transmission. Neurology 1977;27:741-5. (Pubitemid 8165813)
13. Young M, Funder J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology 2003;144:3848-51. (Pubitemid 37088738)
14. Rafael-Fortney JA, Chimanji NS, Schill KE, et al. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation 2011;124:582-8.
15. Pitt B, Bakris G, Ruilope LM, et al. EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118:1643-50.
16. Savoia C, Touyz RM, Amiri F, et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008;51:432-9. (Pubitemid 351156429)
17. Burton LA, McMurdo ME, Struthers AD. Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people? Clin Endocrinol 2011;75:725-9.
18. Imanishi T, Ikejima H, Tsujioka H, et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008;51:734-41. (Pubitemid 351301528)
19. Otte C, Moritz S, Yassouridis A, et al. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 2007;32:232-8. (Pubitemid 44967802)
20. Hlavacova N, Bakos J, Jezova D. Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. J Psychopharmacol 2010;24:779-86.
21. Matono T, Koda M, Tokunaga S, et al. The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat. Int J Mol Med 2010;25:875-82.
22. De Gasparo M, Joss U, Ramjoué HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6. (Pubitemid 17018455)
23. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001;19:185-200. (Pubitemid 34019903)